GlassScriptPhysician profile
Michael S Mullins
NPI 1457390734
$5,334.08
in general payments reported to CMS, 2019-2025
49 companies · $888 in 2025
The $888 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $632 · 2021: $636 · 2022: $775 · 2023: $1,076 · 2024: $809 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.56 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $389.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $364.60 | 2019-2025 | |
| Abbott Laboratories | $363.15 | 2020-2025 | Freestyle Libre 3, Cardiomems |
| Glaxosmithkline, LLC. | $288.06 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $247.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $227.78 | 2020-2025 | Rexulti, Abilify Maintena |
| Horizon Therapeutics Plc | $199.70 | 2020-2022 | |
| Novo Nordisk INC | $176.44 | 2019-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $135.95 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $112.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $99.58 | 2021-2025 | Spravato |
| Antares Pharma, INC. | $96.87 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Axsome Therapeutics, INC. | $92.49 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2019-2024 | Xifaxan, Trulance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.